Biomarkers in Pain: 2nd Edition

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: 30 March 2026 | Viewed by 1904

Special Issue Editors


E-Mail Website
Guest Editor
Department of Surgical Sciences, Anaesthesiogy and Intensive Care Medicine, Uppsala University, 751 85 Uppsala, Sweden
Interests: anesthesiology; biomarkers; coagulation; cytokines; endotoxin; critical care medicine; intensive care; leptin; inflammation; intraosseous; sepsis; SAPS3; shock
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Medical Sciences, Clinical Chemistry, Uppsala University, 751 85 Uppsala, Sweden
Interests: endotoxin; intensive care; acute kidney injury; glomerular filtration rate markers; kidney tubular damage markers; cardiovascular risk markers; neutrophil activation markers; calprotectin
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Acute and chronic pain are two major reasons that patients seek healthcare. Approximately 20% of the world’s population suffers from chronic pain, and in the USA alone, annual economic losses due to chronic pain are estimated to be USD 600 billion. Apart from being a major economic burden for society, chronic pain is also a major cause of decreased quality of life.

Chronic pain is often difficult to treat, and we have few objective measures for evaluating pain levels. Patients in pain therefore often struggle to have their pain problems acknowledged, as pain is a subjective experience that is difficult to verify. During the last decade, biomarkers related to chronic pain have been investigated. The discovery of such markers could not only be used to improve the diagnoses and prognostication of patients with chronic pain, but could also support those who file an insurance claim after an injury. Biomarkers of pain could also be used to distinguish different causes of pain, allowing for an improved selection of treatments. Such markers could also provide pharmaceutical companies with a tool for evaluating pain relief effects in clinical trials.

The focus of this Special Issue of Biomedicines is on the value of biomarkers of pain from a broad perspective.

Biomarkers of pain may be used to identify and quantify pain of various origins in order to facilitate adequate therapeutic interventions. Extensive prescriptions of analgesics, especially opioids, are associated with overdose deaths. Although pain is a subjective experience, the use of determinants of pain as an end point in clinical trials may help to predict the safety as well as the analgesic efficacy of new drugs.

Dr. Mats B. Eriksson
Prof. Dr. Anders O. Larsson
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • analgesia
  • biomarker
  • CSF
  • cytokine
  • inflammation
  • neuropathy
  • neurotransmitter
  • pain
  • QoL
  • sensitization
  • sensory

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 7946 KB  
Article
Neuropathic Pain and Related Depression in Mice: The Effect of a Terpene and a Minor Cannabinoid in Combination
by Jose Rios, Mohammed Alnoud, Mohammad S. Hussain, Zayd Ayas, Emmanuel Franco, Justin Mills, Joshua Nwose, Maria Sophia Malbas, Hiram Garcia, Manish K. Tripathi and Khalid Benamar
Biomedicines 2025, 13(12), 3103; https://doi.org/10.3390/biomedicines13123103 - 16 Dec 2025
Viewed by 236
Abstract
Background/Objectives: Neuropathic pain is one of the most severe types of chronic pain. Although it is difficult to manage, it often co-occurs with depression. Yet, no medication addresses the neuropathic pain and depression comorbidity. Therefore, developing integrated treatment strategies that address both [...] Read more.
Background/Objectives: Neuropathic pain is one of the most severe types of chronic pain. Although it is difficult to manage, it often co-occurs with depression. Yet, no medication addresses the neuropathic pain and depression comorbidity. Therefore, developing integrated treatment strategies that address both pain and depression is a major public health priority and an unmet need affecting millions. Methods: In this study, we investigated the effect of combining a terpene, Beta-Caryophyllene (BCP), and cannabidiol (CBD) on neuropathic pain and associated depression. We employed a chronic constriction injury (CCI) neuropathic pain model and a series of behavioral tests to evaluate how oral administration of this combination influences neuropathic pain and depression-like behaviors in mice. We employed immunohistochemistry and proteomics approaches to explore the mechanism. Results: The analgesic effect of combining CBD and BCP is synergistic in neuropathic pain and also shows an antidepressant effect. Additionally, we found that this combination decreases neuroinflammation associated with CCI and affects specific genes involved in the inflammation. Conclusions: This work provides preclinical scientific evidence supporting the potential usefulness of this combination for neuropathic pain and associated depression. Full article
(This article belongs to the Special Issue Biomarkers in Pain: 2nd Edition)
Show Figures

Figure 1

Review

Jump to: Research

31 pages, 1085 KB  
Review
The Role of the CCR5 Receptor in Neuropathic Pain Modulation: Current Insights and Therapeutic Implications
by Mario García-Domínguez
Biomedicines 2025, 13(11), 2650; https://doi.org/10.3390/biomedicines13112650 - 29 Oct 2025
Viewed by 1359
Abstract
Neuropathic pain, a chronic condition arising from injury or dysfunction of the somatosensory nervous system, is characterized by persistent hypersensitivity and spontaneous pain. The chemokine receptor CCR5 (C-C motif chemokine receptor 5) has recently been identified as a critical mediator in neuroinflammation and [...] Read more.
Neuropathic pain, a chronic condition arising from injury or dysfunction of the somatosensory nervous system, is characterized by persistent hypersensitivity and spontaneous pain. The chemokine receptor CCR5 (C-C motif chemokine receptor 5) has recently been identified as a critical mediator in neuroinflammation and neuropathic pain signaling pathways. Expressed on immune cells and neurons, CCR5 regulates immune cell recruitment and activation, thereby contributing to neuronal sensitization and maintenance of pain states. This review examines the currently characterized molecular mechanisms through which CCR5 modulates neuropathic pain pathophysiology and assesses the potential of CCR5 antagonists as novel therapeutic agents for the management of chronic neuropathic pain. Understanding the involvement of CCR5 in pain modulation may facilitate the development of targeted treatments with improved efficacy and safety profiles. Full article
(This article belongs to the Special Issue Biomarkers in Pain: 2nd Edition)
Show Figures

Figure 1

Back to TopTop